Table 1.
General characteristics of people with T2D and no diabetes
| Men | Women | |||||
|---|---|---|---|---|---|---|
| T2D N = 29,696 n (%) |
No diabetes N = 116,570 n (%) |
p value | T2D N = 25,349 n (%) |
No diabetes N = 99,437 n (%) |
p value | |
| Age (years), mean ± SD | 62.1 ± 10.9 | 62.0 ± 10.9 | 0.06 | 64.9 ± 12.2 | 64.8 ± 12.2 | 0.10 |
| SES | 0.99 | 0.99 | ||||
| Low | 7460 (25) | 29,247 (25) | 6570 (26) | 25,722 (26) | ||
| Normal | 9481 (32) | 37,217 (32) | 8281 (33) | 32,507 (33) | ||
| High | 12,755 (43) | 50,106 (43) | 10,498 (41) | 41,208 (41) | ||
| Patient history in database (years) | 0.24 | 0.28 | ||||
| Mean ± SD | 4.0 ± 2.1 | 4.1 ± 2.1 | 3.9 ± 2.1 | 4.0 ± 2.1 | ||
| Median (IQR) | 3.8 (2.2–5.6) | 3.8 (2.2–5.7) | .24 | 3.6 (2.2–5.4) | 3.6 (2.2–5.5) | |
| Follow-up in database (years) | < .0001 | < .0001 | ||||
| Mean ± SD | 3.7 ± 2.2 | 3.5 ± 2.2 | 3.8 ± 2.2 | 3.7 ± 2.2 | ||
| Median (IQR) | 3.7 (1.9–5.5) | 3.4 (1.7–5.3) | 3.8 (2.0–5.6) | 3.7 (1.8–5.5) | ||
| Year of index date | 0.60 | 0.53 | ||||
| 2007–2008 | 6205 (21) | 24,691 (21) | 5644 (22) | 22,477 (23) | ||
| 2009–2010 | 8528 (29) | 33,612 (29) | 7579 (30) | 29,869 (30) | ||
| 2011–2012 | 8059 (27) | 31,447 (27) | 6598 (26) | 25,688 (26) | ||
| 2013–2014 | 6904 (23) | 26,820 (23) | 5528 (22) | 21,403 (22) | ||
| Co-medicationa | ||||||
| Aspirin | 4972 (17) | 12,303 (11) | < .0001 | 3236 (13) | 8197 (8) | < .0001 |
| Non-aspirin NSAIDs | 6999 (24) | 22,274 (19) | < .0001 | 6594 (26) | 22,092 (22) | < .0001 |
| Statins | 11,626 (39) | 22,828 (20) | < .0001 | 8800 (35) | 15,712 (16) | < .0001 |
| Antihypertensives | 13,208 (44) | 28,925 (25) | < .0001 | 13,469 (53) | 30,609 (31) | < .0001 |
| HRT | – | – | 814 (3) | 3656 (4) | < .01 | |
SD standard deviation, IQR interquartile range, NSAIDs non-steroidal anti-inflammatory drugs, HRT hormone replacement therapy,
aDetermined in the year prior to index date